SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Marksans Pharma Ltd

BSE: 524404 NSE: MARKSANS ISIN: INE750C01026
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Marksans Pharma Ltd belong to?
Marksans Pharma Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Marksans Pharma Ltd a good quality company?
Marksans Pharma Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Marksans Pharma Ltd undervalued or overvalued?
Marksans Pharma Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Marksans Pharma Ltd a good buy now?
Marksans Pharma Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Marksans Pharma Ltd?
Marksans Pharma Ltd revenue growth is 37.6% for FY-2025 , which is above its 5 year CAGR of 22.1% , indicating faster growth.
Q.2 Gross Profit margin of Marksans Pharma Ltd?
Marksans Pharma Ltd Gross profit margin which is the profit after deduction of direct costs, is 23.1% for FY-2025 , which is in line with its 5 year median of 23.1% , indicating stable margins.
Q.3 Operating Profit Margin of Marksans Pharma Ltd?
Marksans Pharma Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 17.72% for FY-2025 , which is above its 5 year median of 17.27% indicating increasing margins.
Q.4 Net Profit Margin of Marksans Pharma Ltd?
Marksans Pharma Ltd Net Profit Margin is 16.03% for FY-2025 , is above with its 5 year median of 15.8%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 23.1 23.1
Operating Profit Margin 17.72 17.27
Net Profit Margin 16.03 15.8
Q.5 Return on Asset of Marksans Pharma Ltd?
Marksans Pharma Ltd Return on Asset is 11.26%, which is in line with its 5 year historical median of 11.26%, indicating stable asset utilization efficiency.
Q.6 Return on Equity (ROE) of Marksans Pharma Ltd?
Marksans Pharma Ltd Return on equity is 14.45% for FY-2025 , which is in line with its historical median of 14.45%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Marksans Pharma Ltd?
Marksans Pharma Ltd Return on capital employed is 18.76% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of Marksans Pharma Ltd?
Marksans Pharma Ltd Cash conversion cycle is 133 days, below its historical median of 133 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.7 0.7
ROE 14.45 14.45
ROCE 18.76 18.76
Cash Conversion Cycle 133 days 133 days
Q.9 Debt to Equity ratio of Marksans Pharma Ltd?
Marksans Pharma Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Marksans Pharma Ltd?
Marksans Pharma Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Marksans Pharma Ltd?
Promoters hold 43.87% of the Marksans Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Marksans Pharma Ltd vs industry peers?
Marksans Pharma Ltd revenue CAGR is 22.06% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 1,174.4 137.1
Gross Profit 271.2 15.1
Operating Profit 204 16
Net Profit 188 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.7 0.8
ROE 14.45 8.91
ROCE 18.76 11.59
Cash Conversion Cycle (days) 133.4 76

Valuation & price assessment

Q.1 Stock return of Marksans Pharma Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 14.4% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 14.4% 26.8% 32.1% -15.2%
Q.3 Valuation ratios of Marksans Pharma Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 33.2 37.48 40.28
Price to Book 5.26 3.86 2.77
Price to Sales 6.39 4.18 2.65
EV to EBITDA 22.49 23.02 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×